Update
Over the past week, new statements from U.S. Health and Human Services Secretary Robert F. Kennedy Jr. have added clarity to earlier reports that tied Acetaminophen (Tylenol) use during pregnancy to Autism Spectrum Disorder (ASD).
Kennedy acknowledged that while some research has explored a possible connection, the evidence isn’t strong enough to show that Tylenol directly causes autism. He encouraged families to make medication decisions in close consultation with their healthcare providers rather than relying on headlines or early-stage findings.
Major health organizations, including the World Health Organization (WHO), share this position. They note that the data so far is inconclusive and that more long-term studies are needed before drawing any firm conclusions about the Tylenol–autism link.
At ABA Centers of America, we understand how confusing and emotional these topics can be for parents. Our commitment remains the same—to provide families with balanced, fact-checked information and compassionate support as research into autism care continues to evolve.
Table of Contents
On Monday, September 22, the Trump administration held a high-profile autism briefing. Promoted as a major update, the event ended up offering more speculation than solid findings. Officials discussed possible links between acetaminophen (Tylenol) use during pregnancy and autism, highlighted early treatment research like leucovorin, and released new prevalence data. At the same time, they acknowledged that autism remains complex, and no single cause has been proven.
According to a USA Today report, Robert F. Kennedy Jr. himself stated that there is “not sufficient proof” linking acetaminophen use during pregnancy with autism.
This article from ABA Centers of America outlines what was said — what still isn’t clear — and where families can find guidance.
Trump Autism Announcement: What Was Said
Acetaminophen (Tylenol) & Pregnancy Risk
During the briefing, President Trump warned expectant mothers about using acetaminophen, stating there is evidence it could be linked to higher autism risk in children. He cautioned that the use of Tylenol in pregnancy should be limited unless medically necessary. Importantly, federal health officials clarified that this is an association, not proof of causation. The FDA has begun the process to update labels on acetaminophen products to reflect that possible association.
Leucovorin as a Possible Therapy
Leucovorin was also spotlighted. It’s a folinic acid derivative being studied in early trials for children with autism—particularly those with folate-pathway anomalies. Some of the information suggests improvements in communication, but autism advocates and clinical experts agree that these findings are preliminary, and more rigorous, well-controlled trials are needed.
Why This Matters for Families
- The most reliable autism prevalence figure today is 1 in 31 children (CDC, 2022).
- Autism is complex. Genetics, prenatal environment, and other factors all contribute. No single exposure or behavior explains it.
- If you are pregnant or planning pregnancy, do not make medication changes without consulting your healthcare provider.
- While early data around leucovorin is promising, it remains experimental. It should not replace proven therapies like Applied Behavior Analysis (ABA).
- Trust sources that balance caution and evidence: independent autism-focused organizations, academic research institutions, and medical authorities.
Our Perspective at ABA Centers of America
We believe in giving families both hope and honesty.
Hope, because research into causes and treatments shows progress is being made.
Honesty, because no single headline—whether it’s “Trump autism breakthrough” or “acetaminophen causes autism”—tells the whole story.
Families deserve balanced information. We encourage parents to ask questions, consult trusted providers, and focus on therapies proven to make a difference right now.
Reaction to Trump’s Autism Press Conference from Autism Organizations and Experts
Autism Speaks, the largest autism advocacy organization in the U.S., released a statement urging caution:
“While associations between acetaminophen and autism have been reported, the evidence is inconsistent and not sufficient to prove causation. Families should consult their doctors before making any medical changes.”
The Autism Science Foundation and other advocacy groups echoed similar concerns, emphasizing that parents should not feel blamed for medical decisions made during pregnancy. They warned that overstating early or inconclusive research risks unnecessary anxiety.
The announcement drew sharp responses from autism researchers, clinicians, and self-advocates.
- Alison Singer (Autism Science Foundation) said the president’s remarks blaming mothers who “couldn’t tough it out” and took acetaminophen during pregnancy were “shocking,” recalling decades-old stigma where mothers were wrongly blamed for autism
- Helen Tager-Flusberg (Coalition of Autism Scientists) described the briefing as “the most unhinged discussion of autism I have ever listened to,” noting the lack of scientific grounding
- Eric Garcia, an autistic journalist, warned that comments framing autism as preventable or describing it as a “horrible crisis” spread stigma and offer families false hope
- Brian Lee, epidemiologist at Drexel University, explained that while some studies show statistical associations between acetaminophen and autism, more rigorous research that accounts for genetics shows those associations often disappear — highlighting the danger of confusing correlation with causation
Trump’s Autism News: What Remains Unclear or Disputed
- Whether acetaminophen/Tylenol causes autism — the evidence so far is associative, not causal
- Exactly how or if leucovorin will move from small trials to approved treatment, and which children might benefit
- The veracity of various claims made during the briefing, including statements about regions with “virtually no autism” or dramatic numbers for boys in certain counties — many remain unverified by peer-reviewed research
- How regulatory and labeling changes will be implemented and communicated in practice
- The extent to which new federal research initiatives, such as NIH’s $50 million autism data science initiative, will influence treatment or policy
Supporting Families Through the Noise
National attention on autism is a good thing, but it can also feel overwhelming. Headlines about Trump’s autism news and “acetaminophen autism study” may spark confusion, fear, or guilt for parents. At ABA Centers of America, we want families to know:
You did not cause your child’s autism
Autism is not explained by one medication or one decision
Evidence-based therapy, like ABA, remains the best path to helping children build skills, independence, and confidence
Final Thoughts
President Trump’s autism briefing was headline-making, but most experts agree it raised more questions than it resolved. Claims about acetaminophen (Tylenol) and other potential factors got attention, but solid, peer-reviewed science is still catching up. Leading autism organizations are calling for tempered interpretation and urging families to focus on what is proven.
Ultimately, while national announcements can change the conversation, the best decisions for your child will come from trusted medical advice and evidence-based care—not from sound bites.
At ABA Centers of America, our mission hasn’t changed: to provide compassionate, evidence-based care that makes a real difference for families living with autism today. As more details emerge about acetaminophen, Tylenol, leucovorin, and autism, we’ll continue to share updates—always with clarity, context, and care.
Don’t hesitate to schedule a consultation today with ABA Centers of America by contacting us online or calling (844) 923-4222.
